Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways.
Drugs that are already clinically approved or experimentally tested for conditions other than cancer, but are found to possess previously unrecognized cytotoxicity towards malignant cells, may serve as fitting anti-cancer candidates.
Fenbendazole, FZ], a benzimidazole compound is a safe and inexpensive anthelmintic drug possessing an efficient anti-proliferative activity
Here, we show that FZ demonstrates a moderate affinity for mammalian tubulin and exerts cytotoxicity to human cancer cells at micromolar concentrations.
The results, in conjunction with our earlier data, suggest that FZ is a new microtubule interfering agent that displays anti-neoplastic activity and may be evaluated as a potential therapeutic agent because of its effect on multiple cellular pathways leading to the effective elimination of cancer cells.